AI Market Mood: Stock Dashboard
ARVN
Fundamental
Company: Arvinas Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -4.67
Insider Own: 13.37%
Shs Outstand: 68.70M
Perf Week: 1.28%
Market Cap: 1.25B
Forward P/E: -
EPS next Y: -4.63
Insider Trans: -0.01%
Shs Float: 59.53M
Perf Month: -3.92%
Income: -308.60M
PEG: -
EPS next Q: -0.96
Inst Own: 101.11%
Short Float: 16.40%
Perf Quarter: -31.33%
Sales: 161.10M
P/S: 7.74
EPS this Y: 52.46%
Inst Trans: 1.66%
Short Ratio: 11.71
Perf Half Y: -29.76%
Book/sh: 8.53
P/B: 2.13
EPS next Y Percentage: -46.99%
ROA: -27.73%
Short Interest: 9.76M
Perf Year: -60.24%
Cash/sh: 16.32
P/C: 1.11
EPS next 5Y: 12.12%
ROE: -59.16%
52W Range From: 16.61
52W Range To: 53.08
Perf YTD: -5.32%
Dividend Est.: -
P/FCF: -
EPS past 5Y: 23.62%
ROI: -52.60%
52W High: -65.81%
Beta: 1.97
Dividend TTM: -
Quick Ratio: 3.62
Sales past 5Y: 50.37%
Gross Margin: 53.69%
52W Low: 9.27%
ATR (14): 1.13
Dividend Ex-Date: -
Current Ratio: 4.17
EPS Y/Y TTM: 15.41%
Oper. Margin: -221.85%
RSI (14): 45.89
Volatility W: 5.02%
Volatility M: 6.24%
Employees: 445
Debt/Eq: 0.00
Sales Y/Y TTM: 0.94%
Profit Margin: -191.56%
Recom: 1.23
Target Price: 61.80
Option/Short: Yes / Yes
LT Debt/Eq: 0.00
EPS Q/Q: 42.32%
Payout: -
Rel Volume: 0.94
Prev Close: 17.10
Sales Surprise: 69.09%
EPS Surprise: 19.31%
Sales Q/Q: 195.95%
Earnings: Feb 11 BMO
Avg Volume: 833.88K
Price: 18.15
SMA20: -0.20%
SMA50: -11.25%
SMA200: -29.59%
Trades:
Volume: 744,181
Change: 6.14%
Technical:
Latest News:
Arvinas,Pfizer update Phase 1b data on vepdegestrant palbociclib combination - Tipranks somewhat bullish
ARVN PFE
Summary: Arvinas and Pfizer presented updated clinical data on vepdegestrant in combination with palbociclib at the 2024 European Society for Medical Oncology Breast Cancer Annual Congress, showing encouraging clinical activity in patients with ER positive/HER2 negative breast cancer.
Full article2024-05-17T12:14:19Z
Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib very bullish
ARVN PFE
Summary: Arvinas, Inc. and Pfizer Inc. announced positive 6-month follow up data from a Phase 1b study evaluating vepdegestrant in combination with Pfizer's breast cancer drug Palbociclib in heavily pre-treated breast cancer patients.
Full article2024-05-16T19:25:38Z